Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention

Lanfranco Pellesi,Messoud Ashina,Paolo Martelletti
DOI: https://doi.org/10.1080/14728214.2024.2317778
2024-02-14
Expert Opinion on Emerging Drugs
Abstract:Introduction The pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) has emerged as a key mediator of migraine pathogenesis. PACAP-38 and its receptors are predominantly distributed in arteries, sensory and parasympathetic neurons of the trigeminovascular system. Phase 2 trials have tested human monoclonal antibodies designed to bind and inhibit PACAP-38 and the pituitary adenylate cyclase-activating polypeptide type I (PAC 1 ) receptor for migraine prevention.
pharmacology & pharmacy
What problem does this paper attempt to address?